May 14, 2024Open Access

Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study was aimed at investigating changes in insulin requirements and glycemic outcomes in adults with type 1 diabetes (T1D) using Control IQ (Tandem Diabetes) automated insulin delivery system (AID) over 8 months of tirzepatide treatment.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Karakus et al. (Tue,) studied this question.

synapsesocial.com/papers/68e6a284b6db643587625e59 https://doi.org/https://doi.org/10.1007/s13300-024-01592-9

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes2024 · 61 citations
2Real-World Evidence of Omnipod <sup>®</sup> 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes2024 · 72 citations
3Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes2022 · 194 citations
4Glucose Monitoring Metrics in Individuals With Type 1 Diabetes Using Different Treatment Modalities: A Real-World Observational Study2023 · 23 citations
5Insulin Requirements for Basal and Auto-Correction Insulin Delivery in Advanced Hybrid Closed-Loop System: 4193 Days’ Real-World Data of Children in Two Different Age Groups2022 · 21 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo